Kojin Therapeutics is a small-molecule therapeutics company focused on translating deep biological insight into the plasticity of human cell states to develop therapeutics for cancer, fibrosis, ischemia and immune modulation.
Dr. Benjamin Cravatt
Dr. Stephanie K. Dougan
Dr. Stuart Schreiber
Dr. Vasanthi Viswanathan
Kojin Therapeutics has raised $60 million to use iron-dependent cell death to treat drug-resistant cancer. The series A round positions the biotech to build on the work its scientific founders did at institutions including Harvard University and the Dana-Farber Cancer Institute.
Ferroptosis has become a hot target in oncology research. In June, Kojin Therapeutics raised $60 million to advance work initiated at Harvard University and the Dana-Farber Cancer Institute that involves using small molecules to destroy cells that are most vulnerable to ferroptosis.
